December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Quantitative Assessment of the Effect of Photodynamic Therapy in Patients With Pathologic Myopia
Author Affiliations & Notes
  • U Schnurrbusch
    Augenklinik University of Leipzig Leipzig Germany
  • H Klopp
    Augenklinik University of Leipzig Leipzig Germany
  • P Wiedemann
    Augenklinik University of Leipzig Leipzig Germany
  • S Wolf
    Augenklinik University of Leipzig Leipzig Germany
  • Footnotes
    Commercial Relationships   U. Schnurrbusch, None; H. Klopp, None; P. Wiedemann, None; S. Wolf, Novartis F, R.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 600. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      U Schnurrbusch, H Klopp, P Wiedemann, S Wolf; Quantitative Assessment of the Effect of Photodynamic Therapy in Patients With Pathologic Myopia . Invest. Ophthalmol. Vis. Sci. 2002;43(13):600.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the short term effects of photodynamic therapy (PDT) of choroidal neovascularization (CNV) secondary to pathologic myopia (PM). Methods: Ten patients with subfoveal CNV due to PM underwent PDT with verteporfin. Patients were followed prospectively for a minimal follow-up of 6 months. Patients were retreated every three months if they had experienced visual deterioration and if angiographic examination demonstrated an active leaking CNV. Follow-up visits were scheduled every three months and two weeks after each PDT treatment. At each follow-up visit all patients underwent digital fluorescein and ICG angiography. To assess treatment effects we have analyzed the size of the classic component of the CNV in all angiograms. Results: During the mean follow-up time of 14 6 months we performed 30 PDT treatments. Initial visual acuity ranged form 20/125 to 20/40. At baseline the size of the CNV ranged from 0.12 to 1.34 mm2 (mean 0.76 0.4 mm2). At two weeks after initial treatment the CNV was totally occluded in 2 eyes, in 5 eyes the size of the CNV was markedly reduced, in two eye no change was noted, and in one eye the CNV increased in size. The mean size at two weeks was 0.36 0.5 mm2. At three months the mean size of the CNV was markedly increased (mean 1.56 0.9 mm2) as compared to baseline. However visual acuity was stable or increased in all patients. Re-treatment at three months resulted in a reduction of the mean CNV size to 0.50 0.7 mm2. At the last follow-up CNV size ranged from 0.09 to 9.12 mm2 (mean: 1.90 2.9 mm2). Final visual acuity ranged from 20/200 to 20/25. No patient had experienced a visual loss (≤ 3 ETDRS lines) during follow-up. Conclusion: Photodynamic therapy with Verteporfin resulted in stabilization or moderate improvement of visual acuity in all patients with PM despite increase of CNV size during follow-up.

Keywords: 516 photodynamic therapy • 481 myopia • 430 imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×